Blog
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP
  • HEMING GROUP

Company News

Industry News

HEMING GROUP

The He Ming Group's Hu Heng Medical GSM multicenter real-world research project and clinical consensus survey on prevention and treatment measures for cervical cancer in perimenopausal and menopausal women were successfully launched.

2025-01-08

　　Recently, a launch meeting (online and offline) for the "GSM Multicenter Real-World Research Project" and the "Clinical Consensus on Prevention and Treatment Measures for Cervical Cancer in Peri-menopausal and Menopausal Women" was successfully held on January 7th at the seventh-floor meeting room of the Jiulong Lake campus of the Jiangxi Provincial Maternal and Child Health Hospital. The meeting was organized by the He Ming Group, Hu Heng Medical, and the Hu Heng-New Vaginal Microecological Prebiotic Sustained-Release Preparation project team. Medical experts attending the on-site meeting included Professor Wang Ning from the National Health Commission's Institute of Science and Technology; Professor Wang Liqun from the Jiangxi Provincial Maternal and Child Health Hospital; Secretary-General Yi Xin from the Obstetrics and Gynecology Branch of the China Association for the Promotion of Birth and Child Health; Professor Zhang Lei from Tsinghua University Affiliated Tsinghua Chang Gung Hospital; and Professor Lian Fang (team) from Shandong University of Traditional Chinese Medicine Affiliated Provincial Hospital of TCM. Corporate guests included Chairman Zhao Xiaoming from Jiangxi He Ming Group; General Manager Wei Ranfei, head of the Hu Heng project at Hu Heng Medical; Professor Yuan Wanjiang from Beijing Huatong Yikang Medical Research Institute; Professor Zhang Lisheng from Li's Pharmaceutical Factory; and Yang Yang, medical director of He Ming Group.

　　This meeting aimed to promote the launch of the GSM multicenter real-world research project and discuss the clinical consensus on prevention and treatment measures for cervical cancer in peri-menopausal and menopausal women. This is of great significance for the current clinical prevention and treatment of cervical cancer in peri-menopausal and menopausal women and will contribute to the development of the medical and health industry. Many medical institutions and experts in related fields participated in the online and offline discussions, including the National Health Commission's Institute of Science and Technology, Tsinghua University Affiliated Chang Gung Hospital, Shanghai Jiao Tong University Affiliated Renji Hospital, Fudan University Affiliated Obstetrics and Gynecology Hospital, Shanghai First Maternity and Infant Hospital, Fengcheng Central Hospital, Dalian Medical University Affiliated Fourth Hospital, China Medical University Affiliated Fourth Hospital, Zhengzhou University Affiliated Second Hospital, Zhengzhou University Affiliated Fifth Hospital, Henan University Affiliated First Hospital, Central South University Xiangya Second Hospital, and Jiangxi Provincial Maternal and Child Health Hospital.

　　After the meeting, an expert group led by Professor Wang Ning from the National Health Commission's Institute of Science and Technology and Professor Wang Liqun from the Jiangxi Provincial Maternal and Child Health Hospital visited He Ming Group for corporate research and provided advice and suggestions on the company's research and development technology, boosting the company's confidence in R&D. This is of great significance for the efficient transition of medical supplies from research and development to production and clinical application.

Previous Page

The Phase II project of Jiangxi and Ming Group's digital production base construction has officially commenced.

Specialized and innovative report

Next Page

Previous Page:

The Phase II project of Jiangxi and Ming Group's digital production base construction has officially commenced.

Next Page:

Specialized and innovative report